Asia
Researchers at Kanazawa University report in Scientific Reports how a particular biochemical signaling pathway cancels biological noise, ensuring the proper stem cell differentiation during development.
System will be Installed at Shonan Kamakura Advanced Medical Center, Scheduled to be Complete in September 2020
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
One day after it was revealed Takeda is moving its U.S. headquarters from Illinois to Boston ahead of the completion of the Shire Plc acquisition, the Japanese company is reportedly considering the sale of Shire’s eye-care business in order to cut some debt incurred from funding the $62 billion deal.
WuXi AppTec congratulates its partner Hutchison MediPharma (HMP) on receiving approval of fruquintinib capsules (Elunate®) for metastatic colorectal cancer from the National Medical Products Administration of China
FMX101 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints
The opposition to Takeda Pharmaceutical acquiring Shire has taken on another dimension with a prominent member of the family that created the Japanese pharmaceutical company speaking publicly against the deal.
Dr Wan Yue joins international CIFAR research programme.
The first stage of the Phase IIa study with YELIVA® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patients who previous received other treatments
PRESS RELEASES